Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
Accession Number
DB14445
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)hemagglutinin3Q80689L6FNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fluarix 2011/2012Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2011-07-012011-07-01Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2010-07-232011-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2010-07-232011-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularPhysicians Total Care, Inc.2010-09-212011-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularPhysicians Total Care, Inc.2010-09-162011-06-30Us
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
FLUZONE High-DoseInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (60 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2010-07-232011-06-30Us
FLUZONE High-DoseInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (60 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2011-07-012012-06-30Us
Categories
UNII
3Q2OMA2GNK
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableMucosal Immunity1
0CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceCentral Nervous System Neoplasms1
1CompletedBasic ScienceFlu caused by Influenza / Healthy Volunteers2
1CompletedPreventionFlu caused by Influenza4
1CompletedPreventionFlu caused by Influenza / Gammopathy1
1CompletedPreventionHealthy Adult Volunteers1
1TerminatedSupportive CareNeoplasms1
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
1, 2CompletedPreventionFlu caused by Influenza5
1, 2RecruitingTreatmentAging Frailty1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma1
2CompletedPreventionBone Marrow Transplant (BMT) / Dialysis therapy / Human Immunodeficiency Virus (HIV) Infections / Rheumatologic Disorders / Solid Organ Transplant Recipient (Liver, Kidney, Heart)1
2CompletedPreventionFlu caused by Influenza14
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection1
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviridae Infections2
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxovirus Infections1
2CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviruses1
2CompletedPreventionHealthy Volunteers1
2CompletedPreventionInfluenza Viral Infections / Malignancies1
2CompletedPreventionInfluenza, Human1
2CompletedPreventionRespiratory Tract Diseases / Respiratory Tract Infections (RTI) / RNA Virus Infections / Virus Diseases1
2CompletedTreatmentFlu caused by Influenza / Monoclonal Gammopathy of Unknown Significance / Multiple Myeloma (MM) / Plasma Cell Dyscrasia / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malignancies1
2RecruitingBasic ScienceHealthy Volunteers1
2RecruitingPreventionFlu caused by Influenza1
3Active Not RecruitingPreventionFlu caused by Influenza / Immunosuppression1
3CompletedEducational/Counseling/TrainingFlu caused by Influenza1
3CompletedPreventionFlu caused by Influenza11
3CompletedPreventionFlu caused by Influenza / Influenza Infection1
3CompletedPreventionFlu caused by Influenza / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Myxovirus Infection / Orthomyxoviridae Infections2
3CompletedPreventionHerpes Zoster2
3CompletedPreventionInfluenza Disease1
3RecruitingPreventionFlu caused by Influenza1
3TerminatedPreventionFlu caused by Influenza1
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Vaccine Response to Either Fluad® (MF59Flu) or Fluzone® (HDFlu)1
4Active Not RecruitingHealth Services ResearchHealthy Volunteers1
4Active Not RecruitingPreventionElderly Immune System1
4Active Not RecruitingPreventionFlu caused by Influenza2
4CompletedBasic ScienceFlu caused by Influenza12
4CompletedBasic ScienceFlu caused by Influenza / Infections, Cytomegalovirus1
4CompletedBasic ScienceImmune Response to Influenza Vaccine / Influenza A Virus Infection / Influenza B Virus Infection1
4CompletedBasic ScienceMELAS Syndrome1
4CompletedBasic ScienceRheumatoid Arthritis1
4CompletedOtherFlu caused by Influenza1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionAdverse Drug Events / Injection Site Reactions / Pain / Quality of Life / Side Effect of Drug1
4CompletedPreventionChronic Heart Failure (CHF)1
4CompletedPreventionFlu caused by Influenza34
4CompletedPreventionFlu caused by Influenza / Orthomyxoviridae Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionImmune Response / Influenza, Human1
4CompletedPreventionInfluenza Prophylaxis1
4CompletedPreventionInfluenza, Human / Transplantation Infection1
4Not Yet RecruitingBasic ScienceFlu caused by Influenza2
4RecruitingNot AvailableFlu caused by Influenza1
4RecruitingBasic ScienceFlu caused by Influenza1
4RecruitingBasic ScienceInfluenza, Human1
4RecruitingOtherSystemic Inflammatory Response1
4RecruitingPreventionPlasma Cell Neoplasms1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentFlu caused by Influenza1
4TerminatedBasic ScienceFlu caused by Influenza1
4TerminatedPreventionFlu caused by Influenza1
4Unknown StatusBasic ScienceFlu caused by Influenza1
4Unknown StatusPreventionHuman Response to Influenza Vaccine1
Not AvailableActive Not RecruitingNot AvailableAstrocytomas / Gliomas / Oligodendrogliomas1
Not AvailableCompletedNot AvailableCentral Nervous System Neoplasms1
Not AvailableCompletedNot AvailableFlu caused by Influenza / H1N1 / Human Immunodeficiency Virus Type 1 (HIV-1) Infection1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedNot AvailableSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedBasic ScienceFlu caused by Influenza2
Not AvailableCompletedBasic ScienceImmune Response2
Not AvailableCompletedBasic ScienceImmunity to Influenza Vaccine1
Not AvailableCompletedOtherFlu caused by Influenza1
Not AvailableCompletedPreventionAtopic Dermatitis (AD)1
Not AvailableCompletedPreventionFlu caused by Influenza2
Not AvailableTerminatedTreatmentHealthy, no Evidence of Disease1
Not AvailableUnknown StatusPreventionCongenital Muscular Dystrophy / Duchenne's Muscular Dystrophy (DMD) / Spinal Muscular Atrophy (SMA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
Injection, suspensionIntramuscular
Injection, suspensionIntradermal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 05, 2018 12:03 / Updated on March 01, 2020 21:50

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates